Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cigarette smoking has been associated with the risk of idiopathic pulmonary fibrosis (IPF). Certain comorbidities have been associated with reduced survival although some studies have indicated that current smokers have a longer survival than ex-smokers. Comorbidities in relation to smoking history have not been previously analyzed. METHODS: Retrospective data was collected and patients were categorized according to gender and smoking habits. Comorbidities and medications were collected. Predictive values for mortality were identified by COX proportional hazard analyses. RESULTS: We examined 45 non-smokers (53.3% female), 66 ex-smokers (9.1% female) and 17 current smokers (17.6% female) with IPF. Current smokers were younger at baseline (58.1 ± 8.74 years) compared to non-smokers (71.4 ± 8.74, p < 0.001) and ex-smokers (72.5 ±7.95, p <0.001). Median survival of non-smokers and current smokers was longer (55.0 and 52.0 months, respectively) than that of ex-smokers (36.0 months) (p=0.028 and 0.034, respectively). In age and severity adjusted analyses, smoking was not related to survival. Cardiovascular diseases (CVD) (72.7 %) were the most common comorbidities, current smokers had more chronic obstructive pulmonary disease (COPD) and lung cancer compared to ex-smokers (p<0.001). CVD, COPD and use of insulin were related to poorer survival in adjusted analyses. CONCLUSIONS: Smoking seems to influence the course of disease in IPF since current smokers developed the disease at a younger age in comparison to non-smokers and ex-smokers. No significant differences in the major comorbidities were detected between IPF patients with different smoking histories. The mechanism through which smoking influences IPF progression requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In our study cohort patients with a rapid disease course used more allopurinol, but allopurinol has not been related to increased risk of death in IPF [15, 29].”
From Comparison of disease progression subgroups in idiopathic pulmonary fibrosis (2019) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853 · cited 6×
“Current smokers were younger compared to those with other smoking histories which meant that age was found to be a significant predictor of survival [3].”
BackgroundResultInfluentialCigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V., & Waldron, J. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.1.9001319 · Cited by 767 · cited 1×
“Background Cigarette smoking has been shown to associate with the risk of developing idiopathic pulmonary fibrosis (IPF) with ever-smokers having a 60 % higher risk [1].”
BackgroundWells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463 · cited 12×
“Our results support the earlier findings that CVDs are the most common comorbidities experienced by IPF patients [7, 28].”
BackgroundResultInfluentialLee, J. S., Ryu, J. H., Elicker, B. M., Lydell, C. P., Jones, K. D., Wolters, P. J., King, T. E., & Collard, H. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0138oc · Cited by 437 · cited 1×
“The use of GER medication and a GER diagnosis have been associated with longer survival times in some previous investigations, but here, they exerted no effect on survival [6, 15].”
ResultImpact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Ehlers-Tenenbaum, S., Palmowski, K., Bruhwyler, J., Oltmanns, U., Muley, T., Heussel, C. P., Warth, A., Kolb, M., & Herth, F. J. F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151425 · Cited by 351 · cited 3×
“have been shown to exhibit worse survival than those not burdened by comorbidities [6].”
BackgroundResultThe Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis
Tomassetti, S., Gurioli, C., Ryu, J. H., Decker, P. A., Ravaglia, C., Tantalocco, P., Buccioli, M., Piciucchi, S., Sverzellati, N., Dubini, A., et al. (2015) · Chest · doi:10.1378/chest.14-0359 · Cited by 314
The Association between Idiopathic Pulmonary Fibrosis and Vascular Disease: A Population-based Study
Hubbard, R. B., Smith, C., Le Jeune, I., Gribbin, J., & Fogarty, A. W. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-725oc · Cited by 238
Spirometric Studies in Non-Smoking, Healthy Adults
Viljanen, A. A., Halttunen, P. K., Kreus, K.-E., & Viljanen, B. C. (1982) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518209168377 · Cited by 237
Cited by
Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis
Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03693-7 · Cited by 351
Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis
Brown, S.-A. W., Dobelle, M., Padilla, M. L., Agovino, M., Wisnivesky, J. P., Hashim, D., & Boffetta, P. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201807-481oc · Cited by 142
Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Zheng, Q., Cox, I. A., Campbell, J. A., Xia, Q., Otáhal, P., de Graaff, B., Corte, T. J., Teoh, A. K. Y., Walters, E. H., & Palmer, A. J. (2022) · ERJ Open Research · doi:10.1183/23120541.00591-2021 · Cited by 148
“N=348 studies were included and assessed for eligibility, and 68 studies [21-88] were finally included in the qualitative analyses.”
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 138
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Kaunisto, J., Salomaa, E.-R. M., Hodgson, U., Kaarteenaho, R. L., Kankaanranta, H., Koli, K. M., Vahlberg, T. J., & Myllärniemi, M. (2019) · ERJ Open Research · doi:10.1183/23120541.00170-2018 · Cited by 121
Self-citation
Metadata
- Authors
- Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R.
- Affiliations
- University of Eastern Finland (FI)
- Kuopio University Hospital (FI)
- Corresponding author
- Kärkkäinen, Miia
- Venue
- Respiratory Research
- Published
- 2017-08-22
- Volume
- 18
- Issue
- 1
- Pages
- 160-160
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC5567897
- OpenAlex
- W2745939486
- Cited by
- 72
- References
- 29
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 3 · 2017: 1
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Respiratory Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- The Foundation of The Finnish Anti-Tuberculosis Association
- The Organization for Respiratory Health in Finland
- the Väinö and Laina Kivi Foundation
- The Kuopio Region Respiratory Foundation
- the Jalmari and Rauha Ahokas Foundation
- Research Director of Kuopio University Hospital
- the state subsidy of Kuopio University Hospital
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, cigarette smoking, smoking status, survival, comorbidities, cardiovascular disease, chronic obstructive pulmonary disease, lung cancer, insulin use, former smokers, disease progression
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Smoking, Comorbidity, Survival Rate, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-017-0642-6
- The paper
- Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R. (2017). Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-017-0642-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.